Stockscreener 앱 받기
9.6335
3.76%
-0.3565
전일 마감가:
$9.99
열려 있는:
$9.67
하루 거래량:
120.12K
Relative Volume:
0.06
시가총액:
$1.17B
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-33.22
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
-3.37%
1개월 성능:
+16.54%
6개월 성능:
+72.92%
1년 성능:
+208.15%
1일 변동 폭
$9.60
$9.97
1주일 범위
$9.30
$10.16
52주 변동 폭
$2.36
$10.16
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
TRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
9.645 | 1.22B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.74 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.18 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.12 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
329.04 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Is Trevi Therapeutics Inc a good long term investmentMarket Timing Techniques & Insights From Wall Street Professionals - earlytimes.in
Is Trevi Therapeutics Inc. stock bottoming out2025 Volatility Report & Long-Term Growth Stock Strategies - newser.com
How to use Fibonacci retracement on Trevi Therapeutics Inc.2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Published on: 2025-10-10 03:52:14 - newser.com
What MACD and RSI say about Trevi Therapeutics Inc.Trade Entry Report & Long-Term Investment Growth Plans - newser.com
Trevi Therapeutics (NASDAQ:TRVI) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Candlestick signals on Trevi Therapeutics Inc. stock todayJuly 2025 Sentiment & Daily Volume Surge Trade Alerts - newser.com
Trevi Therapeutics announces oral presentation and abstracts at Chest 2025 Annual Meeting - MarketScreener
Trevi Therapeutics Announces Oral Presentation And Abstracts At Chest 2025 Annual Meeting - TradingView
Phase 2b CORAL results: Trevi Therapeutics to present nalbuphine ER Oct 21; RIVER 2a PROs poster - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $21.75 Consensus Target Price from Analysts - Defense World
Trevi Therapeutics, Inc. $TRVI Stock Position Boosted by Farther Finance Advisors LLC - Defense World
Trevi Therapeutics Inc. stock trend forecast2025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
Analyzing net buyer seller activity in Trevi Therapeutics Inc.July 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighHere's What Happened - MarketBeat
Trevi Therapeutics stock hits 52-week high at 9.93 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week high at 9.93 USD - Investing.com
What analysts say about Trevi Therapeutics Inc stockBearish Engulfing Patterns & Tap Into the Fastest-Growing Companies - earlytimes.in
Will earnings trigger a reversal in Trevi Therapeutics Inc.Recession Risk & High Return Stock Watch Alerts - newser.com
Regression analysis insights on Trevi Therapeutics Inc. performancePortfolio Return Summary & Low Risk Growth Stock Ideas - newser.com
Rhumbline Advisers Buys 10,608 Shares of Trevi Therapeutics, Inc. $TRVI - Defense World
Analyzing recovery setups for Trevi Therapeutics Inc. investorsTrade Performance Summary & Precise Buy Zone Tips - newser.com
Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut - Yahoo Finance
Custom watchlist performance reports with Trevi Therapeutics Inc.Swing Trade & Reliable Trade Execution Plans - newser.com
Trading Recap: Will Trevi Therapeutics Inc. outperform tech stocksShort Setup & Smart Investment Allocation Tips - خودرو بانک
How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025 - Yahoo Finance
Is Trevi Therapeutics Inc. stock entering bullish territoryIPO Watch & Target Return Focused Picks - newser.com
Quarterly Risk: Will Trevi Therapeutics Inc. outperform its industry peersBull Run & AI Optimized Trade Strategies - خودرو بانک
Hedge Fund Moves: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Stock Summary & Fast Entry Momentum Alerts - خودرو بانک
Long term hold vs stop loss in Trevi Therapeutics Inc.Quarterly Market Review & Fast Gaining Stock Reports - newser.com
Market Recap: Can ProShares Trust ProShares UltraShort Russell2000 grow without dilution2025 Technical Patterns & Safe Capital Growth Stock Tips - khodrobank.com
Market Catalysts: Is Trevi Therapeutics Inc forming a breakout patternPortfolio Gains Report & Fast Moving Stock Trade Plans - khodrobank.com
Combining machine learning predictions for Trevi Therapeutics Inc.Weekly Trade Recap & Low Risk Profit Maximizing Plans - newser.com
Trevi Therapeutics to present two phase 2a River trial posters at ERS Congress 2025 - MarketScreener
Trevi Therapeutics To Present Two Phase 2a River Trial Posters At ERS Congress 2025 - TradingView
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025 - PR Newswire
Trevi Therapeutics to Present Phase 2a RIVER Trial Data on Haduvio for IPF-Related Chronic Cough at ERS Congress 2025 - geneonline.com
Will Trevi Therapeutics Inc outperform its industry peers2025 Trading Recap & Long-Term Capital Growth Strategies - khodrobank.com
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 4.6%Here's What Happened - MarketBeat
Siren L.L.C. Trims Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Fred Alger Management LLC Takes Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Gap Down: What is the PEG ratio of Trevi Therapeutics IncJuly 2025 Movers & AI Powered Trade Plan Recommendations - خودرو بانک
Dividend Watch: How much upside does Sintx Technologies Inc. haveMarket Rally & Risk Controlled Stock Pick Alerts - خودرو بانک
Revenue Check: How does Trevi Therapeutics Inc compare to its peersJuly 2025 Review & Risk Managed Investment Entry Signals - خودرو بانک
Risk Analysis: Will MSAI face regulatory challengesJuly 2025 Spike Watch & AI Driven Price Forecasts - خودرو بانک
Aug Volume: How does Trevi Therapeutics Inc compare to its peersQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - خودرو بانک
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
2.95%
자본화:
|
볼륨(24시간):